Table 1. Baseline Characteristics of Patients With ACS Receiving Clopidogrel or Prasugrel, Before and After Propensity Score Matching.
| Characteristic | Before matching, No. (%) of patients | P value | Standardized difference | After matching, No. (%) of patients | P value | Standardized difference | ||
|---|---|---|---|---|---|---|---|---|
| Clopidogrel (n = 1262) | Prasugrel (n = 1297) | Clopidogrel (n = 901) | Prasugrel (n = 901) | |||||
| Age, mean (SD), y | 69.3 (12.4) | 66.4 (12.7) | <.001 | −0.23 | 68.0 (12.9) | 67.8 (12.6) | .76 | −0.02 |
| ≥75 | 468 (37.1) | 366 (28.2) | <.001 | 303 (33.6) | 296 (32.9) | .73 | ||
| Male | 951 (75.4) | 1049 (80.9) | .001 | 0.14 | 689 (76.5) | 697 (77.4) | .66 | 0.02 |
| BMI, mean (SD) | 23.9 (3.9) | 24.1 (3.8) | .07 | 0.07 | 23.9 (4.1) | 23.9 (3.6) | .84 | 0.009 |
| Weight <60 kg | 549 (44.5) | 465 (36.3) | <.001 | 369 (42.0) | 355 (39.7) | .32 | ||
| Hypertension | 987 (78.2) | 882 (68.0) | <.001 | −0.22 | 658 (73.0) | 658 (73.0) | >.99 | 0.000 |
| Dyslipidemia | 836 (66.2) | 714 (55.1) | <.001 | −0.23 | 540 (59.9) | 545 (60.5) | .81 | 0.01 |
| Diabetes | 375 (29.7) | 340 (26.2) | .05 | 0.08 | 241 (26.7) | 248 (27.5) | .71 | 0.02 |
| Smoker | 422 (33.4) | 489 (37.7) | .03 | 0.09 | 320 (35.5) | 315 (35.0) | .81 | −0.01 |
| COPD | 47 (3.7) | 28 (2.2) | .02 | −0.11 | 25 (2.8) | 24 (2.7) | .89 | −0.008 |
| Chronic kidney disease | 583 (46.2) | 472 (36.4) | <.001 | −0.20 | 369 (41.0) | 365 (40.5) | .85 | −0.009 |
| Family history of coronary artery disease | 154 (12.2) | 169 (13.0) | .55 | 0.025 | 116 (12.9) | 124 (13.8) | .58 | 0.03 |
| Hemoglobin, mean (SD), g/dL | 13.2 (2.3) | 14.0 (2.1) | <.001 | 13.5 (2.3) | 13.8 (2.1) | .006 | ||
| <10 | 110 (8.7) | 55 (4.2) | <.001 | −0.22 | 61 (6.8) | 49 (5.4) | .24 | −0.07 |
| Cerebrovascular disease | 119 (9.4) | 60 (4.6) | <.001 | −0.23 | 50 (5.5) | 56 (6.2) | .55 | 0.03 |
| Peripheral artery disease | 86 (6.8) | 40 (3.1) | <.001 | −0.22 | 40 (4.4) | 36 (4.0) | .64 | −0.03 |
| Previous myocardial infarction | 215 (17.0) | 134 (10.3) | <.001 | −0.22 | 107 (11.9) | 125 (13.9) | .21 | 0.07 |
| Previous heart failure | 93 (7.4) | 30 (2.3) | <.001 | −0.34 | 26 (2.9) | 30 (3.3) | .59 | 0.03 |
| Previous PCI | 345 (27.3) | 194 (15.0) | <.001 | −0.35 | 162 (18.0) | 182 (20.2) | .23 | 0.06 |
| Previous CABG | 32 (2.5) | 17 (1.3) | .03 | −0.11 | 15 (1.7) | 16 (1.8) | .86 | 0.01 |
| Atrial fibrillation | 124 (9.8) | 115 (8.9) | .42 | 0.03 | 75 (8.3) | 85 (9.4) | .41 | 0.04 |
| Cancer | 62 (4.9) | 56 (4.3) | .51 | −0.03 | 43 (4.8) | 40 (4.4) | .74 | −0.02 |
| Transradial intervention | 901 (71.4) | 1098 (84.7) | <.001 | 0.37 | 712 (79.0) | 724 (80.4) | .48 | 0.04 |
| STEMI (vs NSTE-ACS) | 491 (38.9) | 748 (57.7) | <.001 | 0.38 | 417 (46.3) | 417 (46.3) | >.99 | 0.000 |
| Out-of-hospital cardiac pulmonary arrest | 46 (3.6) | 79 (6.1) | .004 | 0.10 | 33 (3.7) | 42 (4.7) | .29 | 0.04 |
| Cardiogenic shock | 98 (7.8) | 110 (8.5) | .52 | 0.03 | 70 (7.8) | 81 (9.0) | .35 | 0.04 |
| VA-ECMO | 29 (2.3) | 19 (1.5) | .15 | −0.07 | 12 (1.3) | 16 (1.8) | .45 | 0.04 |
| Intra-aortic balloon pumps | 130 (10.3) | 144 (11.1) | .52 | 0.03 | 89 (9.9) | 92 (10.2) | .81 | 0.01 |
| Hemodialysis | 54 (4.3) | 28 (2.2) | .002 | −0.15 | 27 (3.0) | 25 (2.8) | .78 | −0.02 |
Abbreviations: ACS, acute coronary syndrome; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; NSTE-ACS, non–ST-segment elevation–acute coronary syndrome; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; VA-ECMO, venoarterial extracorporeal membrane oxygenation.
SI conversion factor: To convert hemoglobin to g/L, multiply by 10.0.